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Abstract: 273 words 
Abstract: 
Background: Prevention of hepatitis C virus (HCV) transmission among people who inject 
drugs (PWID) is critical to eliminating HCV in Europe. We estimate impact of current and 
scaled-up HCV treatment with and without scaling-up opioid substitution therapy (OST) and 
needle and syringe programmes (NSP) across Europe over the next 10 years.  
 
Methods: We collected data on PWID HCV treatment rates, PWID prevalence, HCV 
prevalence, OST and NSP coverage from 11 European settings. We parameterized a HCV 
transmission model to setting-specific data that projects chronic HCV prevalence and 
incidence among PWID.  
 
Results: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) 
to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 
5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. Current 
treatment rates using new direct acting antivirals (DAAs) may achieve observable reductions  
in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia and Amsterdam. 
Doubling HCV-treatment rates will reduce prevalence in other sites (12-24%,  
Belgium/Denmark/Hamburg/Norway/Scotland) but is unlikely to reduce prevalence in 
Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates 
using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites.  
 
Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100pyrs or 
less in 10 years. Moderate to substantial increases in current treatment rates are required to 
achieve the same impact elsewhere, from 1.4-3 times (Czech Republic/France), 5-17 times 
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(France/Scotland/Hamburg/Norway/Denmark/Belgium/Sweden), to 200 times (Finland). 
Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 
20-80%.  
 
Conclusions:  Scale-up of HCV treatment and other interventions is needed in most settings 
to minimise HCV transmission among PWID in Europe. 
 
 
Lay summary: Measuring the amount of HCV in the population of people who inject drugs 
is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of 
both HCV treatment and other interventions that reduce injecting risk (especially opioid 
substitution treatment and provision of sterile injecting equipment). 
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Introduction 
 
Chronic hepatitis C virus (HCV) infection is a leading cause of liver disease and morbidity 
causing more deaths than HIV in the US and other high income countries [1-4].  Preventing 
HCV transmission among people who inject drugs (PWID) is critical for averting future liver 
disease in Europe and elsewhere [5] and new HCV infections in this group[6]. Primary 
prevention through opioid substitution treatment (OST) and high coverage needle and syringe 
programmes (NSP) can reduce HCV transmission among PWID [7, 8] and averts new HCV 
infections,[9] but substantial reductions in HCV prevalence are unlikely to be achieved 
without scaling up HCV treatment [10-15].   
The arrival of highly effective and short duration direct acting antivirals (DAAs) with cure 
rates (sustained viral response or SVR) above 90% for all genotypes has made HCV 
“treatment as prevention” more than a theoretical possibility [16-18].  However, the current 
high cost of DAA regimes (often >€30,000 per treatment regime in higher income countries) 
is a barrier to scaling up treatment in most countries.  European guidelines, that previously 
recommended prioritising DAAs for patients with advanced liver disease, now suggest HCV 
treatment should also be provided to people with a risk of transmitting HCV, such as PWID 
[19, 20].  Although a recent economic model suggested that in general it is more cost-
effective to delay treatment of mild disease until more moderate stages of fibrosis[21], when 
these individuals have on-going transmission risk they should be prioritised for early 
treatment over other patient groups [22].   
 
In this paper, we estimate the current HCV treatment rates and coverage of OST and NSP in 
PWID across 11 sites in Europe. We assess the impact of these and scaled-up HCV treatment 
rates and other primary prevention on HCV prevalence and incidence over the next ten years.  
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Methods 
 
The model 
We used a dynamic deterministic mathematical model of HCV transmission among PWID, 
stratifying PWID according to intervention status (no OST or NSP, on OST, NSP, or both) 
alongside HCV infection and treatment status (susceptible never infected, previously 
infected, chronically infected, on treatment, treatment failure [9, 23]). In three sites (Czech 
Republic, Finland and Sweden) PWID are also stratified by drug type (opioid or 
methamphetamine/amphetamine). PWID enter the model through a constant rate that 
individuals initiate injecting; all PWID are assumed initially susceptible to HCV infection 
(Figure 1a). Susceptible PWID can become infected at a per-capita rate proportional to the 
background prevalence of disease which changes as HCV treatment increases. Transmission 
is reduced by a fixed multiplicative cofactor dependent on OST and NSP status (Figure 1b). 
Once infected, PWID either transition to the chronically infected group (Ab+, RNA+) or 
spontaneously clear infection and transition to the previously infected group (Ab+, RNA-). 
This previously infected group are assumed to be re-infected and clear infection at the same 
rate as susceptible PWID[24-26]. Chronically infected PWID (both primary and re-infection) 
can be treated; if treatment is successful and SVR attained, PWID transition to the previously 
infected group. However, if SVR is not attained PWID transition to the treatment failure 
group. In the baseline model, treatment failures cannot be retreated (Figure 1a); once 
treatment is switched to DAAs we assume treatment failures can be retreated. PWID leave 
the model through permanent cessation of injecting or drug-related or non-drug related 
mortality. All PWID enter the model with no coverage of OST or NSP, and transition 
between the different intervention states (OST and/or NSP) at site-specific fixed per-capita 
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rates (Figure 1b, Tables S1a-S1k). Further details of the model including model equations are 
in the Supplementary materials.  
 
Model parameterisation and calibration 
The model was parameterised to each of the 11 sites (Table 1 and Supplementary Tables S1a-
S1l for site specific information).   
 
For sites with opioid injecting only, 2,500 model parameter sets were randomly sampled from 
the parameter uncertainty distributions (see Tables S1a-S1l). For each parameter set, the 
model was fit to the PWID population size by varying the rate that individuals initiate 
injecting, to OST and NSP coverage levels by varying the recruitment rates onto OST and 
NSP, and to either the chronic or antibody HCV prevalence at a site-specific time-point by 
varying the transmission rate.  For Czech Republic, Finland and Sweden the model was fit to 
more parameters - see Supplementary Materials for further details. HCV incidence was 
estimated from model inputs assuming a stable epidemic except for Amsterdam where 
additional data were available suggesting a decreasing PWID population size and declining 
incidence[15].  
 
In sites with opioid and meth/amphetamine injecting, we assume that baseline risk of HCV 
transmission is the same for all PWID [27-29], there is equal NSP coverage across both types 
of  injectors, but only opioid users can be recruited on to OST.  
 
In all but four sites (Czech Republic, Finland, Sweden and Norway), HCV treatment of 
PWID was modelled only amongst those on OST for initial analyses as in these sites only 
PWID on OST are currently treated.  
9 
 
 
Model projections and analyses 
Data on PWID treatment numbers for each site were scaled to give a rate per 1000 PWID as 
well as percentage of chronic HCV infections treated in 2015/16. By scaling to give a rate 
based on total PWID population size we can easily compare current and projected future 
treatment numbers between all sites. All known increases in treatment prior to 2015 were 
included in the model.  
 
We used the model to project the change in prevalence and incidence between 2016 and 2026 
if treatment is switched from IFN-based therapies to new DAAs (SVR rate 90% (85-95%) 
and current treatment rates per 1000 PWID are either maintained, doubled, or increased to 50 
per 1000 PWID treated annually. Impact projections either assumed current coverages of 
OST and NSP are maintained or OST and NSP are scaled-up to 80% coverage (if not already 
achieved). We determined the annual treatment number (expressed as a rate of treatment per 
1000 PWID) needed to reduce incidence to 2 per 100 person years (2%) by 2026. This is the 
number of treatments annually per 1000 PWID and is therefore constant when projecting to 
2026.  
 
We estimated the z-score associated with the mean difference in chronic prevalence given the 
uncertainty in chronic HCV generated by the model. We categorised a z-score less than 0.5 as 
a modest change (unlikely to be observed), between 0.5-1.5 as a moderate change (may be 
observable), and scores greater than 1.5 or 3.0 as changes that are increasingly and highly 
likely to be observed. 
 
Uncertainty analysis 
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To consider the effect of uncertainty within the underlying parameters, we performed a linear 
regression analysis of covariance on the relative decrease in HCV prevalence and incidence 
between 2016 and 2026 when current treatment rates are doubled. For each site, the 
proportion of each model outcome’s sum-of-squares contributed by each parameter was 
calculated to estimate the importance of each parameter to the uncertainty[30].  
 
 
Results 
Baseline HCV Treatment Rates  
HCV treatment of PWID started at different times across the sites, ranging from 1997 
(Slovenia) to 2009 (Norway) with very few PWID having been treated in Finland. Figure 2 
shows the percentage of chronic HCV prevalent cases among PWID that were treated in 
2015/16 based on data from each site – varying from <0.1% in Finland, to 0.5-2% in Sweden, 
Denmark, Belgium, Norway and Amsterdam, and >5% in Czech Republic and Slovenia.  
 
Model projections 
(a) Chronic HCV prevalence among PWID 
At baseline in 2016, projected chronic prevalence varied from <25% in Czech Republic (21% 
(95% CrI 18-24%)) and Slovenia (16% (11-22%)), to >55% in Finland (56% (53-59%)) and 
Sweden (60% (57-63%)). Figure 3 shows projected baseline and 10 year chronic HCV 
prevalence among PWID in each setting for different levels of scale-up of HCV treatment 
with new DAAs. Figure 4 shows the same projections but with scale-up in OST and NSP 
coverage to 80%. 
 
(i) Switching to DAAs, treatment rate maintained 
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In the majority (8/11) of the sites the difference in projected chronic HCV prevalence after 10 
years if current treatment rates with DAAs remain constant is <5%. In these sites the median 
absolute difference ranges from <1.5% in Finland, Sweden and Belgium up to 3-4% in 
Norway, Denmark, France, Hamburg, and Scotland. This difference is substantially smaller 
than the uncertainty in the baseline chronic HCV prevalence in the sites. This equates to a 
relative decrease of <10% at each site (see Supplementary Materials).  
 
In the remaining three sites (Amsterdam, Czech Republic and Slovenia), there is a much 
greater relative decrease in chronic HCV prevalence between 2016 and 2026 from switching 
to DAAs; 37.5% (26.6-51.8%) in Czech Republic and 49.3% (25.0-98.0%) in Slovenia. In 
Amsterdam, the decreasing population size and concurrent decrease in transmission 
contribute around 90% of the relative decrease of 51.8% (28.7-65.7%) in chronic prevalence 
between 2016 and 2026. These sites have a z-score >3.0 indicating that an observable change 
in chronic prevalence will likely occur by switching to DAAs with current treatment rates.  
 
If all sites switched to DAAs with current treatment rates and concurrently increased OST 
and NSP coverage to 80%, the model projects a reduction in prevalence in all sites, from less 
than 20% in Finland (17.6 (10.0-27.9%)) and Hamburg (19.5% (11.7-27.6%)), 30-50% in 
Scotland, Sweden, France, Norway, Denmark and Belgium, to >50% in Czech Republic and 
Amsterdam, and >75% in Slovenia. The differential benefit of scaling-up OST and NSP 
alongside treatment on reducing chronic HCV prevalence ranges from greater than 10 to less 
than 1.5 times because of baseline coverage. For example, in Finland, Sweden and Belgium 
scaling-up OST and NSP with current HCV treatment rates reduces chronic HCV prevalence 
in 10 years by 17.1%, 31.1% and 48.4% respectively, compared to 0.1%, 1.8% and 4.4% 
reduction without OST and NSP scale-up. In contrast, there is only a small projected 
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improvement in Amsterdam and Czech Republic which already have high coverage of OST 
and NSP (Supplementary Materials Tables S1a-S1k); other sites are projected to improve 
reductions in chronic HCV prevalence from 2-3 times (Slovenia, Hamburg and Scotland) and 
5-6 times in France, Denmark and Norway (Supplementary Materials Table S2).   
 
(ii) Switching to DAAs, treatment rate doubled  
For sites with high baseline chronic prevalence (>55% at baseline) and low treatment rates 
(<1% of chronic infections treated at baseline), for example Sweden and Finland, doubling 
DAA treatment rates has little effect on the projected prevalence in 2026 (0.4% (0.3-0.6%) 
and 5.2% (3.3-10.4%) relative decrease respectively) if OST and NSP are maintained at 
current coverage. For sites with moderate chronic prevalence (30-50% at baseline) and <2.5% 
of chronic infections being treated annually in 2015/16 (Belgium, Denmark, Hamburg, 
Norway, Scotland), doubling DAA treatment rates could reduce chronic HCV prevalence 
from 11.6% relative decrease (Belgium) up to 23.5% (Scotland).   
 
France has a moderate chronic prevalence (47.3%) at baseline and high initial treatment rate 
(4.5% (2.4-8.3%) of all chronic infections treated annually). When their treatment rate is 
doubled with DAAs this yields a greater relative decrease in chronic prevalence than other 
sites with moderate prevalence (36.4% (16.7-85.5%)). The credibility intervals are wide 
because of uncertainty in the estimates of HCV treatment rates.  
 
In Czech Republic and Slovenia, doubling DAA treatment rates is projected to reduce chronic 
prevalence by >90% (Figure 3), and in Amsterdam by 55.8% (32.8-69.6%). 
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Increasing OST and NSP to 80% coverage and doubling DAA treatment rates is projected to 
reduce chronic prevalence between 17.9% (10.3-28.2%) in Finland to 99.5% (91.8%-99.9%) 
in Slovenia. In sites with high baseline treatment rates (Czech Republic and Slovenia), the 
decrease in prevalence is primarily due to doubling treatment rates (97.3% and 91.6% 
decrease in Czech Republic with and without scaled-up OST and NSP, respectively, and 
99.5% and 97.4% in Slovenia). For sites with low baseline treatment rates and low coverage 
of OST and NSP, it is the increase in OST and NSP that drives the decrease in chronic 
prevalence rather than the doubling in treatment rates – in Finland the decrease changes from 
0.4% to 17.9% when additionally scaling-up OST and NSP, from 5.2% to 35.5% in Sweden 
and from 11.6% to 55.6% in Belgium.  
 
(iii) DAA treatment rate 50 per 1000 PWID 
Increasing annual DAA treatment rates to 50 per 1000 PWID with current OST and NSP 
coverage leads to substantial reductions in chronic HCV in all sites (Figure 3). In the high 
prevalence sites of Finland and Sweden chronic prevalence reduces by about half by 2026. 
Conversely, in most moderate prevalence sites (Belgium, Hamburg, Scotland, Norway and 
Denmark) chronic HCV prevalence decreases by 70% or more, although in France the 
decrease is smaller and more uncertain (47.6% (21.7-73.8%)). In low prevalence settings 
(Czech Republic and Slovenia), chronic prevalence is projected to decrease by around 99% 
by 2026.   
 
In projections with OST/NSP scale-up to 80%, prevalence decreases by more than three-
quarters in all sites, with 7/11 sites (Scotland, Denmark, Norway, Belgium, Amsterdam, 
Czech Republic and Slovenia) projecting a decrease of >95%.  
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(b) HCV Incidence among PWID 
Baseline projections of incidence before 2015 agree with observed incidence estimates where 
data were available (Supplementary Materials). Projected changes in incidence from 2016 to 
2026 are shown in Supplementary Figures 2 and 3, without and with scale-up of OST and 
NSP to 80% coverage using DAAs. HCV incidence is projected to remain largely unchanged 
with current OST and NSP coverage in all but 3 sites if current HCV treatment rates are 
maintained using DAAs, however if OST and NSP are scaled-up to 80% coverage, 
projections estimate a relative decrease in incidence of over 35% at all sites.  
 
Figure 5 shows the treatment number per 1000 PWID required in 2016/17 to reduce 
incidence to 2 per 100 pyrs (2%) among PWID by 2026 with and without scale-up of OST 
and NSP to 80% coverage. In Amsterdam, an incidence of 2% (1-3%) was already estimated 
in 2016, and so just switching to DAAs ensured an incidence <2% by 2026 in 99% of model 
runs. In Slovenia, just switching to the new DAAs and maintaining current treatment rates is 
likely to decrease incidence to <2% by 2026 (projected by 78% of model fits), with an 
increase in treatments rates by 20% being needed to ensure this impact in the other 22% of 
model fits. In Czech Republic switching to DAAs would achieve 2% incidence in <10% of 
model fits, and increasing current treatment rates by 43% over all model runs would ensure 
the decrease. In all other sites a substantial increase in HCV treatment rates (in the absence of 
any increase in OST and NSP coverage) is needed to reduce HCV incidence to 2%, ranging 
from 3 to 5 times the current treatment rates in France and Scotland, to between 6-9 times in 
Hamburg, Norway, Denmark, Belgium, 17 times in Sweden, and 200 times in Finland. If 
OST and NSP are scaled-up to 80% coverage, maintaining current treatment rates is 
sufficient to achieve an incidence of 2% in 2026 in Amsterdam and Slovenia (100% of model 
fits), may achieve this impact in Belgium, Czech Republic (84% and 50% of model fits), but 
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is unlikely to (<10% of model fits) in other settings. Alongside increased OST and NSP, 
France, Denmark, Norway, Scotland, Hamburg, Sweden and Finland would need to scale-up 
their baseline treatment rates by 2.2, 2.8, 2.8, 3.6, 4.7, 10.3 and 159-fold, respectively. This is 
20-60% less than if OST and NSP had not been scaled-up.  
 
(c) Uncertainty analysis 
The sensitivity analysis indicates that for most sites, uncertainty in three main factors 
contribute to variation in the relative decrease in chronic prevalence and incidence between 
2016 and 2026 when treatment rates are doubled, but with differing levels of influence 
between the sites (Supplementary Materials Figure S4). The PWID population size 
contributes 34-63% of the variation in Finland, Belgium, Scotland, Slovenia and Norway, and 
80% in Sweden, whilst the prevalence estimates contribute 32-53% of the variation in five of 
the sites (Slovenia, Belgium, Czech Republic, Denmark and Hamburg). The duration of 
injecting is most important in Amsterdam, contributing 85% of the variation, but also 
contributes 25-48% in Scotland, Hamburg, Denmark, Norway, Belgium and Finland.  In 
France, the estimated treatment rate contributes 80% of the variation.   
 
Discussion 
Main Findings 
Treatment scale-up is needed to achieve observable reductions in chronic HCV prevalence 
among PWID in most sites in Europe , even with new DAAs. Doubling DAA treatment rates 
may lead to observable reductions (12-24% decrease) in chronic prevalence by 2026 in 
Belgium, Denmark, Hamburg, Norway and Scotland; but not in Finland or Sweden. 
Exceptions include Czech Republic, Slovenia, and Amsterdam, which at current HCV 
treatment rates are projected to reduce chronic HCV prevalence from a third to a half by 
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2026. This is due to the low or decreasing prevalence of infection in these settings. 
Alternatively, increasing OST and NSP coverage to 80% with current HCV treatment rates 
would reduce chronic HCV prevalence by 17-20% in Finland and Hamburg and 30-79% in 
all other sites. Reducing HCV incidence to less than 2% by 2026 requires little action in 
Amsterdam, Czech Republic and Slovenia, whereas in Belgium, Denmark, Hamburg, 
Norward and Scotland it will require at least a 5-fold increase in current HCV treatment rates, 
or 1.8-4.7-fold if OST and NSP are scaled up to 80% coverage. 
 
Strengths and Limitations 
Our model projections and their interpretation are influenced strongly by uncertainty in the 
parameters and evidence base.  First, we collected information from a range of sources and 
obtained data not routinely collected across Europe (e.g. number of PWID treated for HCV) 
[6, 31].  Unfortunately, data collection was inconsistent across sites, particularly estimates of 
PWID population size which were used to estimate HCV treatment rates.  Reliable PWID 
population size estimates are difficult to obtain and except for Amsterdam where evidence 
suggests a falling population [15, 32], we had to assume stable populations.  
 
Second, uncertainty in the chronic HCV prevalence among PWID contributed substantially to 
the uncertainty in our projections, with estimates generated from a diverse range of sources 
and rarely (except for Scotland) from ongoing community based surveillance [6, 33].  Third, 
the duration of injecting drug use is difficult to estimate precisely and contributed to model 
uncertainty. We sampled the average injecting duration from a range extending from 6 to 
over 20 years, and in the absence of clear evidence assumed that opioid and 
methamphetamine injectors had similar durations.  If the true duration is towards the higher 
end of our ranges, scaling-up HCV treatment will have greater impact on transmission, and if 
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towards the lower end, scaling-up OST and NSP will have a greater contribution on reducing 
transmission [34].   
 
Fourth, DAA SVRs for PWID in “real world” settings are yet to emerge, and so we assumed 
a range of 85-95%[35, 36]. Given the short treatment duration and early treatment of 
predominantly mild disease, it is likely that SVRs will be very high, although it is possible 
that as treatment is scaled-up among more vulnerable PWID this SVR may reduce.  In 
general, the impact of HCV treatment in our projections is relatively robust to variations in 
SVR, although uncertainty in SVR becomes more influential in settings with lower chronic 
prevalence and higher HCV treatment rates. Furthermore, we assumed that PWID who had either 
cleared HCV spontaneously or after successful treatment had the same risk of re-infection as the 
susceptible population of PWID i.e. the per capita transmission probability of re-infection was the 
same as for primary infection.  There is some evidence to suggest that previous spontaneous 
clearance could result in higher rates of clearance for subsequent re-infection[24], but similar data 
surrounding spontaneous clearance of re-infections after SVR does not exist, and infrequent testing 
intervals can contribute bias as some re-infections may go unnoticed[24, 37]. Observational studies 
have reported that re-infection after SVR can be of a similar, higher or lower rate than the 
background rate of infection[38-42], indicating uncertainty in the evidence.  However, if re-infection 
risk was lower than primary infection for people achieving SVR, or spontaneous clearance higher for 
re-infections, then our model projections represent conservative estimates for the number of 
treatments needed to reduce prevalence and incidence across the different sites.   
 
Fifth, we recorded substantial differences in coverage of OST and NSP between sites which 
are incorporated into the baseline model.  In subsequent intervention scenarios, we either 
considered no scale-up of these interventions, or assumed their scale-up to 80% coverage. 
This optimistic scenario may over-estimate the likely impact of what could be achieved from 
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scaling-up OST and NSP, although some of our sites demonstrate such coverage is possible.  
However, even if this scale-up is possible, it is unlikely that it would be achieved quickly, so 
these projections may over-estimate the real reduction in HCV that could be achieved from 
scaling-up OST and NSP.  Sixth, the model does not incorporate information on HCV case-
finding and any future difficulty in diagnosing and treating PWID with chronic HCV when 
HCV transmission and prevalence have fallen to low levels, but this limitation will only 
affect a small number of the most optimistic model projections.  
 
Seventh, we have not modelled HIV co-infection which varies across Europe and may impact 
both on linkage to services and morbidity outcomes.  Finally, we assume no change in 
injecting risk behaviour following HCV treatment – apart from through exposure to OST and 
NSP which is also included prior to HCV treatment.  If injecting risk was reduced following 
treatment [43], our assumption provides conservative projections of impact.   
 
Implications and Comparisons with Other Literature 
Multiple studies in specific countries and across Europe have used statistical and 
mathematical model projections to suggest that new DAA treatments need to increase in 
order to reverse trends in End Stage Liver Disease [44-48]. However, to project impact on 
HCV transmission, a dynamic transmission model that can track both re-infection and 
prevention of future infections is required, alongside information on the number and 
proportion of individuals from key populations like PWID treated for HCV infection.  
Consequently, there are fewer analyses that project impact on HCV transmission.   
 
An earlier study revealed a 2-3 fold difference in chronic HCV prevalence and 4-5 fold 
difference in baseline HCV treatment rates in seven cities in the UK [49].  We also found 
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considerable heterogeneity between sites in Europe. For example, Czech Republic and 
Slovenia both have baseline chronic prevalence of less than 30% [28, 50, 51], whilst in 
Finland and Sweden it is over 55%. Treatment rates also varied 2-3 fold. At baseline, 8/11 
sites had low treatment rates (<10/1000 PWID treated annually), whereas France had a much 
higher treatment rate (21/1000 PWID treated annually), a consequence of the high access to 
HCV treatment in France compared to other countries[52]. Our results also show a greater 
decrease in prevalence for Amsterdam than other studies have projected [15, 53], however 
this could be due to differences in modelling the decreasing epidemic to achieve the 
incidence estimate, and differences modelling the PWID population and transmission 
dynamics. 
 
The lack of ongoing surveillance data, including PWID prevalence and HCV treatment rates 
amongst PWID, in many European settings and comparable indicators between countries is 
important and a public health concern.  Our model projections show that scaling-up OST and 
NSP combined with switching to DAAs with comparatively small increases in the number of 
PWID treated could generate substantial observable reductions in HCV prevalence in several 
sites. However, robust HCV surveillance data among PWID were not always available and 
chronic HCV prevalence was uncertain. To ensure that empirical evidence of the impact of 
HCV treatment as prevention can be generated, it is important that more attention is given to 
establishing robust surveillance systems to reduce the uncertainty surrounding chronic HCV 
prevalence among PWID. The potential and relative costs of introducing effective HCV 
surveillance are trivial compared to the costs of HCV treatment – and need to be encouraged 
across Europe.  
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Tables 
Table 1: Parameter table 
Key parameters used in the modelling for each of the sites. PWID population size and prevalence estimates shows mean (95% CI) unless 
otherwise stated. Mortality rates are given per year. The range for the number of PWID treated per 1000 PWID is estimated using the number of 
treatments in each site and the PWID population size. References are given in Tables S1a-S1k in Supplementary Material.  
Parameter Value Notes 
PWID population size: All sampled from a normal distribution 
Amsterdam 2621 (1946-3374) in 2009 
1874 (1341-2455) in 2014 
 
Belgium 9080 (6356 – 11804)  
Czech Republic 41816 – 46563 Range – no point estimate available 
Denmark 16500 (13000 – 19000)  
Finland 15611 (13770 – 22655)  
France 80000 (65000 – 95000)  
Hamburg 8492 (7582 – 9436)  
Norway 15500 (10500 – 20150)  
Scotland 16000 (11500 – 19400)  
Slovenia 6000 (4200 – 7800)  
Sweden 8021 – 26550 Maximum and minimum PWID population size 
estimates. 
PWID mortality rate: 
 
All sampled from a Poisson distribution 
Amsterdam 2.4% per year  
Belgium 2.5% per year  
Czech Republic 0.8% per year  
25 
 
Denmark 2.0% per year  
Finland 2.0% per year  
France 1.3% per year  
Hamburg 0.7% per year  
Norway 1.9% per year  
Scotland 1.0% per year  
Slovenia 0.7% per year  
Sweden 2.0% per year  
HCV antibody prevalence among PWID and year prevalence fit to 
 
All sampled from a normal distribution.  
In all cases HCV antibody prevalence is adjusted to 
chronic prevalence by assuming a 26% (22-29%) 
spontaneous clearance rate [54] 
Amsterdam 59.4% (54.8 – 64.0%) 2007   
Belgium 43.3% (34.3 – 52.4%) 2012   
Czech Republic 35.0% (31.6 – 38.5%) 2005   
Finland 76.0% (72.4-79.4%) 2014  
France 66.4% (60.3–71.9%) 2011   
Hamburg 67.7% (62.3-72.8%) 2014   
Scotland 58.0% (55.8 – 60.2%) 2013/14  
Slovenia 27.3% (19.1 – 35.5%) mid-2010   
Sweden 81.7% (79.6 – 83.6%) 2014  
HCV chronic prevalence among PWID  
Denmark 35.0 – 45.0% 2014  
Norway 45% (42.6 – 47.5%) 2007  
Number PWID treated per year: 1. Only those on OST are initially eligible for treatment. 
2. All PWID can be treated.  
 Total treated in each 
site per year 
Number treated per 
1000 PWID per year  
 
Amsterdam 2005-2016: 15 2005-2016: 6.1 – 11.2  1. 
Belgium 2004-2016: 30 2004-2016: 5.7 – 10.6 1. 
Czech Republic 2002-2011: 370 2002-2011: 7.9 – 8.8  
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2011-2016: 540 2011-2016: 11.6 – 
12.9 
2. 
Denmark 2002-2014: 53 
2014-2015: 50 
2014-2016: 100 
2002-2014: 2.8 – 4.1 
2014-2015:2.6-3.8 
2014-2016: 5.3-7.7 
1. 
 
Finland 2006-2016: 5 2006-2016: 0.06 1. 
France 2001-2016: 1705 
(923 – 3148) 
2001-2016:10.5 – 43.3   
1. 
Note: these are the calculated number treated based on 
the treatment rate for people who have injected at least 
one in the last year.  
 
Hamburg 2005-2011: 60 
2011-2016: 72 
2005-2011: 6.2 – 7.9 
2011-2016: 7.6 – 9.5 
1. 
Norway 2009-2016: 100 2009-2016: 5.0 – 9.5 70% treatment are amongst those on OST and 30% 
treatment amongst those not on OST. 
Scotland 2005-2008: 60  
2008-2009: 90  
2009-2016: 150 
2005-2008: 3.1 – 5.2 
2008-2009: 4.6-7.8 
2009-2016: 7.7-13.0 
1. 
Slovenia 1997-1999: 2 
1999-2008: 5 
2008-2016: 62 
1997-1999: 0.3 – 0.5 
1999-2008: 0.6 – 1.2 
2008-2016: 7.9 – 14.8 
 
2. 
Sweden 1997-2016: 90 1997-2016: 3.4 – 11.2 2. 
27 
 
Figure legends 
Figure 1: Schematics of HCV transmission (1a) and OST and NSP interventions (1b) in 
the model 
Figure 1a: Infection component of the model 
Figure 1b: OST and NSP intervention component of the model 
 
 
Figure 2: Percentage of estimated PWID with chronic HCV infections treated annually 
at baseline (2015/16) for each site. Bars indicate the median and interquartile range and 
whiskers show the 95% credibility intervals.  
 
 
Figure 3: Baseline and projected 10 year chronic HCV prevalence among PWID in 
multiple sites in Europe for various treatment intervention scenarios.  Baseline chronic 
prevalence (blue boxes) and projected 10 year chronic prevalence if either current treatment 
rates continue with new DAAs (green boxes), treatment rates are doubled with new DAAs 
(yellow boxes), or increased to 50 per 1000 PWID annually with new DAAs (pink boxes). 
Bars indicate the median and interquartile range and whiskers show the 95% credibility 
intervals.  
 
Figure 4: Baseline and projected 10 year chronic HCV prevalence among PWID in 
multiple sites in Europe for various treatment intervention scenarios with OST and 
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NSP scaled-up to 80% coverage.  Baseline chronic prevalence (blue boxes) and projected 
10-year chronic prevalence if either current treatment rates continue with new DAAs (green 
boxes), treatment rates are doubled with new DAAs (yellow boxes), or increased to 50 per 
1000 PWID annually with new DAAs (pink boxes) with OST and NSP scaled-up to 80% 
coverage. Bars indicate the median and interquartile range and whiskers show the 95% 
credibility intervals.  
 
 
 
Figure 5: Current and projected number of treatments per 1000 PWID to reduce 
incidence to 2 per 100 pyrs by 2026. Current number of treatments per 1000 PWID at 
baseline (2015/16, blue) and required scale-up in number of treatments per 1000 PWID 
initially needed per year (2016/17) if current OST and NSP coverage is maintained (green, 
median and 95% credibility interval shown in figure) or if OST and NSP are scaled to 80% 
coverage (yellow) to reduce incidence to 2 per 100 pyrs (2%) by 2026. Based on data from 
the sites we have: 1Treatment initially given only to those on OST. 2Treatment initially given 
to all PWID. 370% treatment to PWIDs on OST, 30% treatment to PWIDs not on OST.  
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Figures 
1a and 1b 
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Figure 5 
 
Purple: Number of treatments per 1000 
PWID at baseline (2015/16) 
Green: Number of treatments needed per 
1000 PWID in 2016/17 with 
current OST and NSP. 
Yellow: Number of treatments needed per 
1000 PWID in 2016/17 with 80% 
coverage OST and NSP.  
 
